Advertisement

Feasibility and Outcomes of Orthotopic Ileal Neobladder Reconstruction Following Pelvic Irradiation

Published:September 23, 2020DOI:https://doi.org/10.1016/j.urology.2020.09.014

      OBJECTIVES

      To evaluate the complications and oncologic outcomes of orthotopic ileal neobladder reconstruction (ONB) following pelvic radiotherapy (RT) compared to patients with no prior pelvic RT.

      METHODS

      Our institutional database was queried for all patients with pT0-4bN0-3M0 urothelial carcinoma of the bladder who underwent radical cystectomy with curative intent and ONB between 1990 and 2018. We then queried this cohort for patients who had prior pelvic RT (>3900 cGy) and compared baseline characteristics, perioperative complications, and recurrence free survival between patients with and without prior pelvic RT.

      RESULTS

      One thousand eight hundred and forty-six patients matched our inclusion criteria; 34 had prior pelvic RT with a median dose of 6280 cGy. Prior RT targeted the bladder, prostate, and cervix in 27, 6, and 1 patient, respectively. Median time from RT to cystectomy was 15.5 months. Patients with prior RT had a longer time from diagnosis to cystectomy, more frequently had ≥5 TURBT and neoadjuvant chemo, and less frequently had multifocal disease. Perioperative complications including operative time, estimated blood loss, days hospitalized, as well as 30- and 90-day complication rates, were not statistically different. There was no statistical difference in recurrence free survival between the 2 groups (P = .48).

      CONCLUSION

      ONB in highly selected patients with prior pelvic RT is feasible with statistically similar perioperative complication rates compared to ONB without prior RT.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American Cancer Society
        Cancer Facts & Figures 2020.
        American Cancer Society, Atlanta, GA2020
        • National Comprehensive Cancer Network
        Bladder Cancer: NCCN Guidelines. Version 3.2020.
        National Comprehensive Cancer Network, Fort Washington, PA2020
        • Mak RH
        • Hunt D
        • Shipley W
        • et al.
        Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
        J Clin Oncol. 2014; 32: 3801-3809
        • Studer UE
        • Burkhard FC
        • Schumacher M
        • et al.
        Twenty years experience with an ileal orthotopic low pressure bladder substitute—lessons to be learned.
        J Urol. 2006; 176: 161-166https://doi.org/10.1016/s0022-5347(06)00573-8
        • Lee RK
        • Abol-Enein H
        • Artibani W
        • et al.
        Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes.
        BJU Int. 2013; 113: 11-23https://doi.org/10.1111/bju.12121
        • Hautmann RE
        • Volkmer BG
        • Schumacher MC
        • et al.
        Long-term results of standard procedures in urology: the ileal neobladder.
        World J Urol. 2006; 24: 305-314
        • Cahn DB
        • Handorf EA
        • Ghiraldi EM
        • et al.
        Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
        Cancer. 2017; 123: 4337-4345
        • Mak KS
        • Smith AB
        • Eidelman A
        • et al.
        Quality of life in long-term survivors of muscle-invasive bladder cancer.
        Int J Rad Oncol Biol Phys. 2016; 96: 1028-1036
        • Giacalone NJ
        • Shipley WU
        • Clayman RH
        • et al.
        Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience.
        Eur Urol. 2017; 71: 952-960
        • Kulkarni GS
        • Hermanns T
        • Wei Y
        • et al.
        Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic.
        J Clin Oncol. 2017; 35: 2299-2305https://doi.org/10.1200/jco.2016.69.2327
        • Ghodoussipour S
        • Ahmadi N
        • Hartman N
        • et al.
        Factors influencing intraoperative conversion from planned orthotopic to non-orthotopic urinary diversions during radical cystectomy.
        World J Urol. 2018; 37: 1851-1855https://doi.org/10.1007/s00345-018-2582-2
        • Chang DS
        • Lawrentschuk N
        Orthotopic neobladder reconstruction.
        Urol Annal. 2015; 7: 1-7
        • Hautmann RE
        • de Petriconi R
        • Volkmer BG
        Neobladder formation after pelvic irradiation.
        World J Urol. 2008; 27: 57-62